



BINGHAM MEMORIAL HOSPITAL
Experience Bingham!

Delivered via email

August 27, 2015

Re: BMH, Inc. dba Bingham Memorial Hospital; 340B ID CAH 131325

Dear Manufacturers:

I am writing on behalf of BMH, Inc. dba Bingham Memorial Hospital 340B ID CAH 131325 (“BMH”) to inform manufactures that BMH recently underwent an audit by the Health Resources and Services Administration (HRSA) of BMH’s compliance with 340B Drug Pricing Program (340B Program) requirements.

As background, BMH qualified for the 340B Program as a Critical Access Hospital, with supportive clinics and contract pharmacies. The entity type and location are described in the enclosed attachment:

BMH began participation in the 340B Program September 8, 2010.

Through the audit process, BMH was found to have non-compliance within their 340B Program and responsible for repayment as a result of the following findings: **BMH dispensed a 340B drug to an ineligible individual, as prohibited by 42 USC 256b(a)(5)(B).**

BMH has identified all affected manufacturers and has contacted each to notify them of these violations to begin a dialogue on a method for repayment to affected manufacturers. If manufacturers have not received notification from BMH and believe repayment may be owed for the violations described in this letter, or if you have any questions or comments regarding the violations described in this letter please contact Mr. Wade Flowers, Pharmacy Director, at 208-782-3770 or you may mail him at the address at the bottom of this letter.

Sincerely yours

D. Jeffery Daniels
Chief Financial Officer

CC: Wade Flowers